'Her2 status' presentation slideshows

834 views • 51 slides

560 views • 40 slides

Study sponsored by Aventis Oncology, RP56976-V-316 / TAX 316

BCIRG 001 Study. Phase III Trial Comparing TAC with FAC in the Adjuvant Treatment of Node Positive Breast Cancer Patients: Interim Analysis.

437 views • 28 slides

Il punto di vista dell'anatomo patologo Anna Sapino

Il punto di vista dell'anatomo patologo Anna Sapino. La determinazione dello stato di HER2 deve essere effettuata sempre al momento della diagnosi sul tumore primario.

306 views • 18 slides

Il punto di vista dell'anatomo patologo Anna Sapino

Il punto di vista dell'anatomo patologo Anna Sapino. La determinazione dello stato di HER2 deve essere effettuata sempre al momento della diagnosi sul tumore primario.

297 views • 18 slides

Van Cutsem E et al. ASCO 2009; Abstract LBA4509. (Oral Presentation)

Efficacy Results from the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy (CT) in First-Line Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer (GC). Van Cutsem E et al. ASCO 2009; Abstract LBA4509. (Oral Presentation). Introduction.

388 views • 17 slides

2 years later, she noticed multiple 1.5 -2 cm. nodular masses at the MRM site.

189 views • 12 slides

Breast Intergroup (N9831) Edith A. Perez, PI

Phase III Trial of Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Paclitaxel With or Without Trastuzumab as Adjuvant Treatment for Women With HER?2 Overexpressing Node-Positive Breast Cancer. Breast Intergroup (N9831) Edith A. Perez, PI.

212 views • 11 slides